Skip to main content

01-10-2019 | Respiratory | Video

ERS 2019: uILD benefits from antifibrotic treatment

Toby Maher discusses the uILD phase 2 trial of pirfenidone in patients with progressive fibrosing unclassifiable interstitial lung disease (uILD), the results of which have been published in The Lancet (5:19).

Funding for independent interviews at ERS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.